Clinical trial
A Phase 1b/2 Trial of the IRX-2 Regimen and Pembrolizumab in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT03918499 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Trial of the IRX-2 Regimen and Pembrolizumab in Patients With Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Lead sponsor
- City of Hope Medical Center
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 19, 2019
- Completion date
- February 9, 2023
- Enrollment
- 9 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iv gastric cancer ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva gastric cancer ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, clinical stage ivb gastric cancer ajcc v8, clinical stage ivb gastroesophageal junction adenocarcinoma ajcc v8, metastatic gastric adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma, pathologic stage iv gastric cancer ajcc v8, pathologic stage iv gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ivb gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv gastric cancer ajcc v8, postneoadjuvant therapy stage iv gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb gastroesophageal junction adenocarcinoma ajcc v8, recurrent gastric adenocarcinoma, recurrent gastroesophageal junction adenocarcinoma